Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martinez-Horta Saul, Horta-Barba Andrea, Perez-Perez Jesús, Sampedro Frederic, de Lucia Natascia, De Michele Giuseppe, Kehrer Stefanie, Priller Josef, Migliore Simone, Squitieri Ferdinando, Castaldo Anna, Mariotti Caterina, Mañanes Veronica, Lopez-Sendon Jose Luis, Rodriguez Noelia, Martinez-Descals Asunción, Garcia-Ruiz Pedro, Júlio Filipa, Januário Cristina, Delussi Marianna, de Tommaso Marina, Noguera Sandra, Ruiz-Idiago Jesus, Sitek Emilia J, Nuzzi Angela, Pagonabarraga Javier, Kulisevsky Jaime, Cognitive Phenotype Working Group of the European Huntington’s Disease Network
Аннотация
OBJECTIVES: We aimed to explore the utility of the Parkinson's disease-Cognitive Rating Scale (PD-CRS) for the screening of global cognition in HD.
METHODS: A multicenter cohort of 132 HD patients at different disease stages and 33 matched healthy controls were classified as having preserved cognition, mild cognitive impairment (HD-MCI) or dementia (HD-Dem) according to the Clinical Dementia Rating and Functional Independence Score. The PD-CRS and the Mini-Mental State Examination were administered. Receiver operating characteristic curve analysis was used to determine optimal cutoffs to differentiate patients according to their cognitive status.
RESULTS: A PD-CRS cutoff score ≤ 81/82 was optimal to detect HD-MCI (sensitivity = 93%; specificity = 80%; area under the curve (AUC) = 0.940), and ≤ 63/64 was optimal to detect HD-Dem (sensitivity = 90%; specificity = 87%; AUC = 0.933). MMSE scores failed to show robust psychometric properties in this context.
DISCUSSION: The PD-CRS is a valid and reliable instrument to assess global cognition in HD in routine clinical care and clinical trials.